ArticleGut pathogens2026
Bacterial and fungal biomarkers in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): trans-kingdom interactions, Blastocystis carriage, and enterotype-succinotype stratification.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome, encompassing bacteria, fungi, and protists, is integral to gastrointestinal (GI) health and disease. While bacterial dysbiosis is well documented in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fungal contributions and bacterial-fungal interactions remain underexplored, particularly in non-Western populations. We profiled bacterial (16S rRNA) and fungal (ITS) communities from stool samples of Saudi participants with IBS, ulcerative colitis (UC), Crohn’s disease (CD), and controls. Analyses incorporated bacterial enterotypes, succinotypes, and Blastocystis carriage to explore ecological and metabolic stratification. Differences in community composition were largely explained by GI disorder, host factors, enterotype, and Blastocystis carriage, accounting for 1–9% of bacterial and fungal variation. IBS patients exhibited increased bacterial richness and evenness, whereas UC and CD displayed stronger fungal dysbiosis. Enterotyping identified two Bacteroides-dominant clusters: Bact1 (with Faecalibacterium, Alistipes) and Bact2 (enriched in Escherichia-Shigella, Streptococcus), with Bact2 linked to reduced diversity and elevated calprotectin. Succinotyping distinguished Dialister-dominant (D-type) and Phascolarctobacterium-dominant (P-type) communities; UC was enriched in fragile, bridge-dependent D-type networks, in contrast to resilient, short-chain fatty acid (SCFA)- and H2S-producing P-type networks. Blastocystis was detected in 48% of participants (mainly subtypes 1 (ST1) and ST3). It was associated with enrichment of butyrate-producing bacteria (Roseburia, Anaerobutyricum, Butyribacter) and distinct fungal genera, with subtype-specific signatures (ST1 enriched in Alistipes, ST3 in Escherichia-Shigella). Disease-associated biomarkers included UC-linked depletion of butyrate producers and enrichment of Cutibacterium, Comamonas, and Dialister; depletion of Clostridia UCG-014 in CD; and enrichment of fermentative fungi (Candida, Meyerozyma) and bacteria (Coprococcus, Catenibacterium) in IBS. Cross-domain networks were resilient and modular in controls and IBS but fragile in UC and intermediate in CD. These findings highlight trans-kingdom interactions and Blastocystis carriage as ecological features of the gut microbiome in IBS and IBD, with enterotype-succinotype stratification offering complementary biomarkers for disease classification in a non-Western cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.